The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Open accessAbstract
Importance: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for cancer screening or prevention. Objective: To determine the proportion and potential clinical implications of inherited variants detected using simultaneous sequencing of the tumor and normal tissue ("tumor-normal sequencing") compared with genetic test results based on current guidelines. Design, Setting, and Participants: From January 2014 until May 2016 at Memorial Sloan Kettering Cancer Center, 10 336 patients consented to tumor DNA sequencing. Since May 2015, 1040 of these patients with advanced cancer were referred by their oncologists for germline analysis of 76 cancer predisposition genes. Patients with clinically actionable inherited mutations whose genetic test results would not have been predicted by published decision rules were identified. Follow-up for potential clinical implications of mutation detection was through May 2017. Exposure: Tumor and germline sequencing compared with the predicted yield of targeted germline sequencing based on clinical guidelines. Main Outcomes and Measures: Proportion of clinically actionable germline mutations detected by universal tumor-normal sequencing that would not have been detected by guideline-directed testing. Results: Of 1040 patients, the median age was 58 years (interquartile range, 50.5-66 years), 65.3% were male, and 81.3% had stage IV disease at the time of genomic analysis, with prostate, renal, pancreatic, breast, and colon cancer as the most common diagnoses. Of the 1040 patients, 182 (17.5%; 95% CI, 15.3%-19.9%) had clinically actionable mutations conferring cancer susceptibility, including 149 with moderate- to high-penetrance mutations; 101 patients tested (9.7%; 95% CI, 8.1%-11.7%) would not have had these mutations detected using clinical guidelines, including 65 with moderate- to high-penetrance mutations. Frequency of inherited mutations was related to case mix, stage, and founder mutations. Germline findings led to discussion or initiation of change to targeted therapy in 38 patients tested (3.7%) and predictive testing in the families of 13 individuals (1.3%), including 6 for whom genetic evaluation would not have been initiated by guideline-based testing. Conclusions and Relevance: In this referral population with selected advanced cancers, universal sequencing of a broad panel of cancer-related genes in paired germline and tumor DNA samples was associated with increased detection of individuals with potentially clinically significant heritable mutations over the predicted yield of targeted germline testing based on current clinical guidelines. Knowledge of these additional mutations can help guide therapeutic and preventive interventions, but whether all of these interventions would improve outcomes for patients with cancer or their family members requires further study. Trial Registration: clinicaltrials.gov Identifier: NCT01775072.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citationCOSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationKalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., Herman, G. E., Hufnagel, S. B., Klein, T. E., Korf, B. R., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.190 · Cited by 1,644
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Germline Mutations in Predisposition Genes in Pediatric Cancer
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508054 · Cited by 1,345 · cited 4×
“Pathogenic variants by tumor type 205 Adrenocortical (1), ampullary (1), biliary (6), bladder (10), breast (19), colorectal (10), endometrial (4), esophagogastric (6), melanoma (1), mesothelioma (1), non–small cell lung (2), ovarian (7), pancreatic (49), paraganglioma (1), prostate (75), renal cell (23), small-bowel (…”
BackgroundInfluentialSelf-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Niu, B., Ye, K., Zhang, Q., Lu, C., Xie, M., McLellan, M. D., Wendl, M. C., & Ding, L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt755 · Cited by 832
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Birt-Hogg-Dubé syndrome: diagnosis and management
Menko, F. H., van Steensel, M. A., Giraud, S., Friis-Hansen, L., Richard, S., Ungari, S., Nordenskjöld, M., Hansen, T. V., Solly, J., & Maher, E. R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70188-3 · Cited by 590
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Self-citationParsons, D. W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., Kerstein, R. A., Gutierrez, S., Petersen, A. K., Bavle, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5699 · Cited by 491
Personalized genomic analyses for cancer mutation discovery and interpretation
Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7161 · Cited by 415
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Schrader, K. A., Cheng, D. T., Joseph, V., Prasad, M., Walsh, M., Zehir, A., Ni, A., Thomas, T., Benayed, R., Ashraf, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5208 · Cited by 339
Self-citationWang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338
Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A. M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw018 · Cited by 195
Cheng, D. T., Prasad, M., Chekaluk, Y., Benayed, R., Sadowska, J., Zehir, A., Syed, A., Wang, Y. E., Somar, J., Li, Y., et al. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0271-4 · Cited by 158
Self-citationPilarski, R., Cebulla, C. M., Massengill, J. B., Rai, K., Rich, T. A., Strong, L. C., McGillivray, B. C., Asrat, M., Davidorf, F. H., & Abdel‐Rahman, M. H. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22129 · Cited by 111
Seifert, B. A., O’Daniel, J. M., Amin, K. D., Marchuk, D. S., Patel, N. M., Parker, J. S., Hoyle, A. P., Mose, L. E., Marron, A., Hayward, M. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0015 · Cited by 100
Revealing the Incidentalome When Targeting the Tumor Genome
Bombard, Y., Robson, M. E., & Offit, K. (2013) · JAMA · doi:10.1001/jama.2013.276573 · Cited by 68
Self-citationThe DNA Helicase Recql4 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation
Ng, A. J., Walia, M., Smeets, M. F. M. A., Mutsaers, A. J., Sims, N. A., Purton, L. E., Walsh, N. C., Martin, T. J., & Walkley, C. R. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005160 · Cited by 47
The future of clinical cancer genomics
Offit, K. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.002 · Cited by 28
Self-citation
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationTargeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5801 · Cited by 667
Self-citation
Metadata
- Authors
- Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., Balakrishnan, A. R., Syed, A., Prasad, M., Nafa, K., Carlo, M. I., Cadoo, K. A., Sheehan, M., Fleischut, M. H., Salo-Mullen, E., Trottier, M., Lipkin, S. M., Lincoln, A., Mukherjee, S., Ravichandran, V., Cambria, R., Galle, J., Abida, W., Arcila, M. E., Benayed, R., Shah, R., Yu, K., Bajorin, D. F., Coleman, J. A., Leach, S. D., Lowery, M. A., Garcia-Aguilar, J., Kantoff, P. W., Sawyers, C. L., Dickler, M. N., Saltz, L., Motzer, R. J., O’Reilly, E. M., Scher, H. I., Baselga, J., Klimstra, D. S., Solit, D. B., Hyman, D. M., Berger, M. F., Ladanyi, M., Robson, M. E., & Offit, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-05
- Volume
- 318
- Issue
- 9
- Pages
- 825
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2753565653
- Cited by
- 511
- References
- 29
- FWCI
- 30.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.